Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2021-04, Vol.56 (4), p.974-977
Main Authors: Ghafouri, Sanaz, Timmerman, John, Larson, Sarah, Mead, Monica D.
Format: Article
Language:English
Subjects:
631/67/1059/2325
692/699/1541/1990/291
Care and treatment
Cell Biology
Cell therapy
Cellular therapy
Central nervous system diseases
Correspondence
Development and progression
Hematology
Internal Medicine
Lymphocytes T
Lymphoma
Medicine
Medicine & Public Health
Methods
Non-Hodgkin's lymphoma
Non-Hodgkin's lymphomas
Patient outcomes
Public Health
Stem Cells
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-01099-4